@thetrickster
Thanks again for your thoughts, much appreciated
1- As I said in my previous reply to you, all the other manufacturers can sell OTC online the same as Nuheara, the only differential at present is Nuheara is the only one that can be sold in store and online. The in store segment will change very shortly.
2- Sorry to disagree - IQ Boost had Ear ID in 2018, nothing has changed since then apart from the charging case, 1 extra microphone and software updates. I think it is very relevant that none of the big 5 hearing companies now stock Nuheara, I dont quite understand how you see that as irrelevant, specifically when you say NUH is an assistive sale - if that is indeed the case, there is no better assistive sale or captive audience than where people go to get their hearing checked out. If your eyes get blurry, you go see an qualified optician, if you cant hear properly you go see an audiologist, therefore common sense dictates that the product should and must sit in an audiology envirnoment as that is the perfect place to sell from. I totally dissagree that Best Buy/Walmart are the best places to sell this device, it may seem correct looking in from the outside, and it may seem ok stating their huge amount of stores, but they have ben in these USA stores before, with the same product, just not approved, and it has failed to shine. You would be far better placed and sell much more product from 12800 amplifon and specsavers stores that you ever will in walmart and best buy, as the demographic is all wrong in those two stores and it is not the first port of call for anyone with a hearing impairment.
3- I understand Nuh focus, however, that focus was misguided waiting for something to happen in the USA, whilst failing to implement and register sales in any other country worldwide. Again it is not irrelevant. It shows a complete lack of vision and perhaps reality from the Directors.Everyone knows you have a strategic product roll out to prove you have a product that sells and can sell in the required numbers to be successful. That has never ever been proven, in fact almost the opposite. You only have to look at the sales income to verify that. The world is a big place, if you want to focus on the USA alone, and not prove that your product sells everywhere else whilst waiting for market entry and clearance from FDA, then there should have been skeleton staff procedures in place, and minimum /maximum salary requirments until such times as they had achieved that goal. Instead you have salaries at circa 400k per annum, running costs that are out of control and do not reflect income and so on and so forth. Why would someone get paid 400,000 a year for continually producing failure? The only notable achievment over the last six years is that they have managed ( somehow) to persuade people to fund them to get to this stage. In between then, looking at the accounts, some of the top execs have been paid over the term circa 2.5 million dollars plus a lot of expenses.
4- In relation to realtek, all the chipset players have deals with hearing companies, Mediatek for example have deals with Mimi, Mediatek being the 4th largest IC in the world, realtek being 9th. Have a look at Mimi accounts and judge for yourself as to what money assitive hearing generates for license agreement. Will realtek put the product inside TV - no - inside car audio - maybe ( thats what i hope for) It could be interesting.
As i keep saying but you keep deflecting, you can look back at history and take the relevant parts and form opinion, other than ignoring it and saying FDA is the holy grail, if it was, the share price would reflect that, which it does not. Why? Because seasoned investors look back historically, and form balanced judgements based on fact. Any other company that received FDA approval for a medical device would have sky rocketed in value on that announcement, it didnt because it has not been proved in any way shape or form, that the product can actually sell, which is has not done over the last 6 years. The chain of events was IQ buds is first model its not good next one will sell, IQ2 is no good wait for boost it will sell, boost is no good wait for max it will sell, max is no good wait for PRO, HP is no good wait for FDA , FDA is here its no good lets wait for Realtek to license. It becomes a never ending cycle of the next one is the winner, and the shareprice is only a relection of what has gone before. So it is best not to ignire it, and just say, it was not done correctly, we have learned from our mistakes and moved on. However, looking at what is going on now, is in fact a repetition of what has gone before which is worying.
Iam in, i have my shares, i think Luna was a very good appointment for numerous reasons, but i dont want to hear about this products not it wait until the next one arrives its the a winner, i want to see the product sell, indeed any product sell, and for it to be sold in places where it has the best opportunity to be sold, as then, and only then, will we as shareholders see a return.
Expand
(20min delay)